Kazuya Sakai

Has grant

Senior Lecturer

Nara Medical University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kazuya Sakai is a Senior Lecturer at Nara Medical University in Japan. His research focus encompasses immune-mediated thrombotic thrombocytopenic purpura (iTTP), particularly the utilization of caplacizumab and the role of ADAMTS13 in its management. He has contributed to several recent publications investigating diagnostic and treatment guidelines, as well as mechanisms underlying thrombotic microangiopathy and therapeutic interventions in patients with TTP.

Recent Grants

Grant: Close

Open Date: 2022-04-01

Close Date: 2023-03-01

Grant: Close

Comprehensive transracial immunoprofile analysis for anti-ADAMTS13 autoantibodies found in immune-mediated thrombotic thrombocytopenic purpura

Open Date: 2022-04-01

Close Date: 2024-03-01

Grant: Close

Validation study of the open ADAMTS13 conformation assay as a novel biomarker for correct diagnosis and predicting relapse in immune mediated thrombotic thrombocytopenic purpura

Open Date: 2021-06-01

Close Date: 2022-05-01

Grant: Close

The recognition mechanism of the susceptible HLA in immune-mediated thrombotic thrombocytopenic purpura to ADAMTS13 peptide

Open Date: 2021-04-01

Close Date: 2023-03-01

Grant: Close

Inhibitory effect on platelet thrombosis formation of a novel DNA aptamer with artificial nucleic acid bases that binds to the von Willebrand factor A1 domain

Open Date: 2019-04-01

Close Date: 2021-03-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Claudia Tersteeg

Assistant professor

Katholieke Universiteit Leuven - Campus Arenberg

BELGIUM

View details

Kazuki Tanaka

head Physician

JAPAN

View details

Masanori Matsumoto

Nara Medical University

JAPAN

View details

Hiroko Miyadera

Assistant Professor

University of Tsukuba

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kazuya Sakai

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project).

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.

Immune‐mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report

Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy

Haematopoietic regeneration by <scp>HLA</scp>‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura

Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity.

Toward gene therapy for congenital thrombotic thrombocytopenic purpura

Overlapping ADAMTS13 peptide binding profiles of DRB108:03 and DRB111:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura

Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023

Open ADAMTS13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Toward gene therapy for congenital thrombotic thrombocytopenic purpura.

Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.

Age and composition of the thrombus retrieved by mechanical thrombectomy from patients with acute ischemic stroke are associated with revascularization and clinical outcomes.

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia

Collaborators (4)

Claudia Tersteeg

Kazuki Tanaka

Masanori Matsumoto

Hiroko Miyadera

Make your next move.

Kazuya Sakai

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project).

Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy.

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.

Immune‐mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report

Excessive cleavage of von Willebrand factor multimers by ADAMTS13 may predict the progression of transplant-associated thrombotic microangiopathy

Haematopoietic regeneration by <scp>HLA</scp>‐A*0206‐deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura

Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity.

Toward gene therapy for congenital thrombotic thrombocytopenic purpura

Overlapping ADAMTS13 peptide binding profiles of DRB1*08:03 and DRB1*11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura

Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023

Open ADAMTS13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura.

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Toward gene therapy for congenital thrombotic thrombocytopenic purpura.

Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.

Age and composition of the thrombus retrieved by mechanical thrombectomy from patients with acute ischemic stroke are associated with revascularization and clinical outcomes.

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia

Collaborators (4)

Claudia Tersteeg

Kazuki Tanaka

Masanori Matsumoto

Hiroko Miyadera

Make your next move.

Overlapping ADAMTS13 peptide binding profiles of DRB108:03 and DRB111:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura